Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

December 31, 2014

Conditions
Carcinoma, Transitional Cell
Interventions
DRUG

Vinflunine

Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min).

OTHER

Undefined (standard care)

All the current interventions used by each institution for the study disease.

Trial Locations (20)

13005

H. General Universitario de Ciudad Real, Ciudad Real

15706

Complejo Hosp. Univ. de Santiago de Compostela, Santiago de Compostela

28007

Hospital General Universitario Gregorio Marañon, Madrid

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

31002

Clínica Universitaria de Navarra (CUN), Pamplona

31008

Complejo Hospitalario de Navarra, Pamplona

41009

H. Universitario Virgen de la Macarena, Seville

41013

H. Universitario Virgen del Rocío, Seville

46009

IVO, Valencia

03600

Hospital General de Elda Virgen de la Salud, Elda

08916

ICO-Hospital Universitari Germans Trias i Pujol, Badalona

08908

ICO-Hospital Duran i Reynals, L'Hospitalet de Llobregat

08243

Hospital Fundació Althaia, Manresa

08208

Corporació Sanitaria Parc Taulí, Sabadell

08003

H. del Mar (Fundació Institut Mar d´Investigacions Mèdiques - FIMIM), Barcelona

08035

H. Universitari Vall d'Hebrón, Barcelona

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

07010

Hospital Universitari Son Espases, Palma de Mallorca

All Listed Sponsors
lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT01529411 - Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter